Skip to main content
padlock icon - secure page this page is secure

Trends in Biotechnological Drugs for Cancer Treatment

Buy Article:

$68.00 + tax (Refund Policy)

Background: Biotechnology, which promoted revolutions in many fields, generates great expectations for the future, mainly in the pharmaceutical sector for the treatment of several diseases. Cancer is a leading cause of death worldwide and due to its complexity and singularity, there are a number of challenges that limit the development of new drugs for antitumor therapies, making the research for cancer treatment one of the most exploited in the medical field. Objective: The main objective of this article is to identify trends of biotechnological advances that may have application in improving cancer therapies. Method: Information from patent applications of biotechnological drugs in the last five years was retrieved using Thomson Reuters Integrity database. Results: Cancer is the leading therapeutic condition found in patent documents. The subject matter most cited in patent applications includes monoclonal antibodies, adoptive cell therapy, RNA interference and new vaccine peptides. Conclusion: The analysis of the documents has provided an overview of new biological alternatives for use in cancer treatment, showing potential avenues for years to come.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antibodies; RNAi; biotechnology; cancer; patents; peptides; proteins; vaccine

Document Type: Research Article

Publication date: February 1, 2016

More about this publication?
  • Recent Patents on Anti-Cancer Drug Discovery publishes review articles on recent patents in the field of anti-cancer drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-cancer drug design and discovery.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more